The US meningococcal vaccines market is expected to grow over the forecast period due to the introduction of pentavalent vaccines from late 2023. The introduction of these products could improve protection against disease caused by serogroup B if uptake matches the higher coverage rates observed with the booster dose of MenACWY in adolescents (59.7% in 2023) versus the suboptimal coverage rates with MenB vaccines (32.4% of 17-year-olds reported having received at least one MenB dose in 2023). The pentavalent vaccines could be more convenient for physicians and patients as they would reduce the total number of doses required during adolescence from four (two MenACWY + two MenB) to three (two primary doses plus a booster).

The five major European markets (France, Germany, Italy, Spain, and the UK) all recommend the routine use of MenACWY and MenB vaccines in adolescents, which will drive growth over the forecast period. Of note, Sanofi is hoping that more countries will switch from monovalent serogroup C vaccines to MenQuadfi in toddlers, but the case for that is currently somewhat mixed. The impact of pentavalent vaccines is unclear as they are likely to add complexity to some immunization schedules, but these vaccines could save money versus separate injections, and combined with greater convenience they could lead to improved vaccination coverage rates and thus higher sales growth.

This Datamonitor Healthcare report contains a Disease Analysis module.